Etanercept - Pfizer

Drug Profile

Etanercept - Pfizer

Alternative Names: Enbrel; p75TNFR-Ig; rhu TNFR-Fc; Soluble tumour necrosis factor receptor p75 Fc IgG1 fusion protein; TNF receptor fusion protein; TNFR-Fc-p75; TNR-001

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Pantec Biosolutions; Pfizer; University of Leeds
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Graft-versus-host disease
  • Phase II Discoid lupus erythematosus
  • No development reported Metabolic syndrome
  • Discontinued Adult-onset Still's disease; Asthma; Behcet's syndrome; Cachexia; Heart failure; Myasthenia gravis; Pulmonary fibrosis; Septic shock; Transplant rejection; Wegener's granulomatosis

Most Recent Events

  • 16 Jun 2018 Pfizer completes a phase II trial in Discoid lupus erythematosus in United Kingdom (Intradermal)
  • 03 Nov 2017 Adverse events data from the phase IIIb CLIPPER2 open-label extension trial in Juvenile rheumatoid arthritis presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
  • 09 Oct 2017 Amgen completes a phase III trial for Psoriatic arthritis, Rheumatoid arthritis in USA and Puerto Rico (SC) (NCT02986139)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top